Allstate Investment Management’s NovoCure NVCR Stock Holding History

Allstate Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$290K	Buy	+3,956	New	+$298K	0.01%	554

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $652M AUM 36.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allstate Investment Management's NVCR Position: Q4 2022 in Review

Allstate Investment Management opened a new position in NovoCure (NVCR) in Q4 2022: 3,956 shares worth $290K. The stake represents 0.01% of the portfolio and ranks #554 among its holdings.

303 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

Allstate Investment Management held 3,956 shares of NovoCure worth $290K as of Q4 2022.
NovoCure was a new Allstate Investment Management position in Q4 2022.
NovoCure made up 0.01% of Allstate Investment Management's portfolio in Q4 2022, its #554 holding.
303 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.